The purpose of this study is to dynamically observe the dynamic changes of serum IGF-1 after intracerebral hemorrhage, explore the impact and correlation of serum IGF-1 with the severity of the patient's condition and prognosis, and provide a reference for clinical treatment timing.
Aged 18 to 75 years old;
Patients with intracerebral hemorrhage (NIHSS ≥5 points);
No history of cerebrovascular diseases with residual functional impairment before brain injury;
Hospitalized within 72 hours after injury;
Patients with severe cardiac, hepatic, renal, or pulmonary dysfunction;
Glycated hemoglobin >9.0% at screening;
History of hypothalamic-pituitary related diseases or severe endocrine diseases;
Use of drugs affecting endocrine function (such as glucocorticoids, growth hormones) within the past six months;
Patients with intracerebral hemorrhage from Shengjing Hospital Affiliated to China Medical University and those from Northern Theater General Hospital
Other
Prospective
Not listed
The relationship between serum IGF-1 levels within 3 days after intracerebral hemorrhage and the severity of the condition (referring to NIHSS score)
Serum IGF-1 levels decrease in the acute phase after intracerebral hemorrhage, and the decrease is correlated with the severity of the condition. (The more severe the condition, the larger the number of patients with reduced IGF-1 levels, and the more significant the decrease in IGF-1 values.)，The higher the IGF-1 level, the lower the NIHSS score.
The correlation between the dynamic change trend of IGF-1 after intracerebral hemorrhage and the prognosis of patients
Patients with persistently decreasing IGF-1 levels have worse functional prognosis than those with persistently normal IGF-1 levels.
Click on the lead sponsor to view all of their trials.
This trial is not recruiting at the moment. You can still explore other options:
